Updates are available Correction dated 2023-04-28
Click to view Correction: https://doi.org/10.1136/jitc-2021-002838corr1
-
Authors
Levy, Gabriel https://orcid.org/0000-0001-6746-3083
Guglielmelli, Paola
Langmuir, Peter
Constantinescu, Stefan N https://orcid.org/0000-0002-8599-2699
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04438629 at ClinicalTrials.govnct04358614 at ClinicalTrials.govDocuments that mention this clinical trial
JAK inhibitors and COVID-19
https://doi.org/10.1136/jitc-2021-002838
nct04401579 at ClinicalTrials.govDocuments that mention this clinical trial
JAK inhibitors and COVID-19
https://doi.org/10.1136/jitc-2021-002838
nct04421027 at ClinicalTrials.govDocuments that mention this clinical trial
JAK inhibitors and COVID-19
https://doi.org/10.1136/jitc-2021-002838
IL-6 modulation for COVID-19: the right patients at the right time?
https://doi.org/10.1136/jitc-2020-002285
nct04469114 at ClinicalTrials.govDocuments that mention this clinical trial
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
https://doi.org/10.1136/jitc-2021-002630
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
https://doi.org/10.1136/ard-2023-223850
JAK inhibitors and COVID-19
https://doi.org/10.1136/jitc-2021-002838
IL-6 modulation for COVID-19: the right patients at the right time?
https://doi.org/10.1136/jitc-2020-002285
Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects
https://doi.org/10.1136/rmdopen-2023-004045
nct04362137 at ClinicalTrials.govDocuments that mention this clinical trial
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
https://doi.org/10.1136/ard-2023-223850
JAK inhibitors and COVID-19
https://doi.org/10.1136/jitc-2021-002838
nct04377620 at ClinicalTrials.govDocuments that mention this clinical trial
JAK inhibitors and COVID-19
https://doi.org/10.1136/jitc-2021-002838
nct04402866 at ClinicalTrials.govDocuments that mention this clinical trial
JAK inhibitors and COVID-19
https://doi.org/10.1136/jitc-2021-002838
Documents that mention this clinical trial
Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial
https://doi.org/10.1136/bmjresp-2023-001627
Large scale clinical trials: lessons from the COVID-19 pandemic
https://doi.org/10.1136/bmjresp-2022-001226
JAK inhibitors and COVID-19
https://doi.org/10.1136/jitc-2021-002838
-
Funding
Funding for this research was provided by:
Ludwig Institute for Cancer Research
Walloon Excellence in Life Sciences and Biotechnology (WelBio F 44/8/5 - MCF/UIG – 10955)
Salus Sanguinis
Stichting Tegen Kanker
Fédération Wallonie-Bruxelles (Action de Recherche concertée (ARC) 16/21-073)
Fondation "les Avions de Sébastien"
- License Information
